CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Total revenue	$ 1,453	$ 1,777
Costs and expenses:
Cost of revenue	1,155	1,202
Research and development	14,306	7,838
General and administrative	6,099	4,827
Revaluation of contingent consideration	(1,200)	16,439
Total costs and expenses	20,360	30,306
Loss from operations	(18,907)	(28,529)
Other income (expense), net	118	(225)
Net loss	$ (18,789)	$ (28,754)
Net loss per share, basic	$ (0.31)	$ (0.57)
Net loss per share, diluted	$ (0.31)	$ (0.57)
Weighted average common shares outstanding, basic	61,431,026	50,337,807
Weighted average common shares outstanding, diluted	61,431,026	50,337,807
Other comprehensive loss:
Unrealized loss on marketable securities, net of tax of $0	$ (748)	$ (35)
Foreign currency translation adjustment		(11)
Total other comprehensive loss	(748)	(46)
Comprehensive loss	(19,537)	(28,800)
Contract research
Total revenue	1,221	1,535
Other revenue
Total revenue	$ 232	$ 242